TY - JOUR
T1 - Ancillary therapy and supportive care of chronic graft-versus-host disease
T2 - National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: V. ancillary therapy and supportive care working group report
AU - Couriel, Daniel
AU - Carpenter, Paul A.
AU - Cutler, Corey
AU - Bolaños-Meade, Javier
AU - Treister, Nathaniel S.
AU - Gea-Banacloche, Juan
AU - Shaughnessy, Paul
AU - Hymes, Sharon
AU - Kim, Stella
AU - Wayne, Alan S.
AU - Chien, Jason W.
AU - Neumann, Joyce
AU - Mitchell, Sandra
AU - Syrjala, Karen
AU - Moravec, Carina K.
AU - Abramovitz, Linda
AU - Liebermann, Jerry
AU - Berger, Ann
AU - Gerber, Lynn
AU - Schubert, Mary
AU - Filipovich, Alexandra H.
AU - Weisdorf, Daniel
AU - Schubert, Mark M.
AU - Shulman, Howard
AU - Schultz, Kirk
AU - Mittelman, Barbara
AU - Pavletic, Steven
AU - Vogelsang, Georgia B.
AU - Martin, Paul J.
AU - Lee, Stephanie J.
AU - Flowers, Mary E.D.
N1 - Funding Information:
This project was supported by the National Cancer Institute, National Institutes of Health (NIH), Office of the Director, Cancer Therapy Evaluation Program, Intramural Research Program, and Center for Cancer Research; National Heart Lung and Blood Institute, Division of Blood Diseases and Resources; Office of Rare Diseases, NIH, Office of the Director; National Institute of Allergy and Infectious Disease, Transplantation Immunology Branch, and the Health Resources and Services Administration, Division of Transplantation and the Naval Medical Research Center, C. W. Bill Young/Department of Defense Marrow Donor Recruitment and Research Program. The authors also like to acknowledge the following individuals and organizations that by their participation made this project possible: American Society for Blood and Marrow Transplantation, Center for International Bone and Marrow Transplant Research, Blood and Marrow Transplant Clinical Trials Network, Canadian Blood and Marrow Transplant Group, European Group for Blood and Marrow Transplantation, Pediatric Blood and Marrow Transplant Consortium, and representatives of the South American transplant centers (Luis F. Bouzas, MD, and Vaneuza Funke, MD). This project was conducted in coordination with the American Society for Clinical Oncology and the American Society of Hematology (liaisons, Michael Bishop, MD, and Jeff Coughlin). The organizers are also indebted to patients and patient and research advocacy groups who made this process much more meaningful by their engagement. Special thanks also to Paula Kim who coordinated these efforts.
PY - 2006/4
Y1 - 2006/4
N2 - The Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidelines for ancillary therapy and supportive care in chronic graft-versus-host disease (GVHD), including treatment for symptoms and recommendations for patient education, preventive measures, and appropriate follow-up; (2) to provide guidelines for the prevention and management of infections and other common complications of treatment for chronic GVHD; and (3) to highlight the areas with the greatest need for clinical research. The definition of "ancillary therapy and supportive care" embraces the most frequent immunosuppressive or anti-inflammatory interventions used with topical intent and any other interventions directed at organ-specific control of symptoms or complications resulting from GVHD and its therapy. Also included in the definition are educational, preventive, and psychosocial interventions with this same objective. Recommendations are organized according to the strength and quality of evidence supporting them and cover the most commonly involved organs, including the skin, mouth, female genital tract, eyes, gastrointestinal tract, and lungs. Recommendations are provided for prevention of infections, osteoporosis, and steroid myopathy and management of neurocognitive and psychosocial adverse effects related to chronic GVHD. Optimal care of patients with chronic GVHD often requires a multidisciplinary approach.
AB - The Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidelines for ancillary therapy and supportive care in chronic graft-versus-host disease (GVHD), including treatment for symptoms and recommendations for patient education, preventive measures, and appropriate follow-up; (2) to provide guidelines for the prevention and management of infections and other common complications of treatment for chronic GVHD; and (3) to highlight the areas with the greatest need for clinical research. The definition of "ancillary therapy and supportive care" embraces the most frequent immunosuppressive or anti-inflammatory interventions used with topical intent and any other interventions directed at organ-specific control of symptoms or complications resulting from GVHD and its therapy. Also included in the definition are educational, preventive, and psychosocial interventions with this same objective. Recommendations are organized according to the strength and quality of evidence supporting them and cover the most commonly involved organs, including the skin, mouth, female genital tract, eyes, gastrointestinal tract, and lungs. Recommendations are provided for prevention of infections, osteoporosis, and steroid myopathy and management of neurocognitive and psychosocial adverse effects related to chronic GVHD. Optimal care of patients with chronic GVHD often requires a multidisciplinary approach.
KW - Allogeneic cell transplantation
KW - Chronic graft-versus-host disease
KW - Consensus
KW - Supportive care
UR - http://www.scopus.com/inward/record.url?scp=33644905065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644905065&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2006.02.003
DO - 10.1016/j.bbmt.2006.02.003
M3 - Review article
C2 - 16545722
AN - SCOPUS:33644905065
SN - 1083-8791
VL - 12
SP - 375
EP - 396
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 4
ER -